{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:26:11Z","timestamp":1792106771163,"version":"4.4.0"},"reference-count":179,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi231033-4\"><jats:title>Importance<\/jats:title><jats:p>This is the first network meta-analysis to assess outcomes associated with multiple conventional synthetic disease-modifying antirheumatic drugs and glucocorticoid.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231033-5\"><jats:title>Objective<\/jats:title><jats:p>To analyze clinical outcomes after treatment with conventional synthetic disease-modifying antirheumatic drugs and glucocorticoid among patients with rheumatoid arthritis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231033-6\"><jats:title>Data Sources<\/jats:title><jats:p>With no time restraint, English language articles were searched in MEDLINE, Embase, Cochrane Central, ClinicalTrials.gov, and reference lists of relevant meta-analyses until September 15, 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231033-7\"><jats:title>Study Selection<\/jats:title><jats:p>Four reviewers in pairs of 2 independently included controlled studies randomizing patients with rheumatoid arthritis to mono\u2013conventional synthetic disease-modifying antirheumatic drugs, glucocorticoid, placebo, or nonactive treatment that recorded at least 1 outcome of tender joint count, swollen joint count, erythrocyte sedimentation rate, and C-reactive protein level. Of 1098 assessed articles, 130 articles (132 interventions) were included.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231033-8\"><jats:title>Data Extraction and Synthesis<\/jats:title><jats:p>The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline, and data quality was assessed by the Cochrane risk of bias tool RoB 2. Data were extracted by a single author and checked independently by 2 authors. Data were analyzed using a random effect model, and data analysis was conducted from June 2021 to February 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231033-9\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>A protocol with hypothesis and study plan was registered before data recording. The most complete of recorded outcomes (tender joint count) was used as primary outcome, with imputations based on other outcomes to obtain a full analysis of all studies. Absolute change adjusted for baseline disease activity was assessed.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231033-10\"><jats:title>Results<\/jats:title><jats:p>A total of 29 interventions in 275 treatment groups among 132 randomized clinical trials (mean [range], 71.0% [27.0% to 100%] females in studies; mean [range] of ages in studies, 53 [36 to 70] years) were identified, which included 13\u202f260 patients with rheumatoid arthritis. The mean (range) duration of RA was 79 (2 to 243) months, and the mean (range) disease activity score was 6.3 (4.0 to 8.8). Compared with placebo, oral methotrexate was associated with a reduced tender joint count by 5.18 joints (95% credible interval [CrI], 4.07 to 6.28 joints). Compared with methotrexate, glucocorticoid (\u22122.54 joints; 95% CrI, \u22125.16 to 0.08 joints) and remaining drugs except cyclophosphamide (6.08 joints; 95% CrI, 0.44 to 11.66 joints) were associated with similar or lower tender joint counts.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231033-11\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This study\u2019s results support the present role of methotrexate as the primary reference conventional synthetic disease-modifying antirheumatic drug.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.35950","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:31:08Z","timestamp":1696606268000},"page":"e2335950","source":"Crossref","is-referenced-by-count":9,"title":["Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis"],"prefix":"10.1001","volume":"6","author":[{"given":"Louise S.","family":"Guski","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesche","family":"J\u00fcrgens","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Pedder","sequence":"additional","affiliation":[{"name":"Department of Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels K. G.","family":"Levinsen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig E.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky J.","family":"Welton","sequence":"additional","affiliation":[{"name":"Department of Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Graudal","sequence":"additional","affiliation":[{"name":"Center for Rheumatology and Spine Diseases, The Lupus and Vasculitis Clinic, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"issue":"5661","key":"zoi231033r1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0140-6736(01)24417-1","article-title":"The treatment of rheumatoid arthritis with gold salts injections.","volume":"219","author":"Forestier","year":"1932","journal-title":"Lancet"},{"issue":"8","key":"zoi231033r2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(24)00526-3","article-title":"The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis.","volume":"24","author":"Hench","year":"1949","journal-title":"Proc Staff Meet Mayo Clin"},{"issue":"2","key":"zoi231033r3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/00045391-200103000-00007","article-title":"Old and new drugs used in rheumatoid arthritis: a historical perspective: part 1: the older drugs.","volume":"8","author":"Case","year":"2001","journal-title":"Am J Ther"},{"issue":"5","key":"zoi231033r4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1046\/j.1440-1711.2003.01184.x","article-title":"Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus.","volume":"81","author":"Mottram","year":"2003","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"zoi231033r5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.v73.7","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"zoi231033r6","first-page":"47","article-title":"Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: longterm course and association to radiographic progression.","volume":"27","author":"Graudal","year":"2000","journal-title":"J Rheumatol"},{"key":"zoi231033r7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03009740310004847","article-title":"The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins.","volume":"118","author":"Graudal","year":"2004","journal-title":"Scand J Rheumatol Suppl"},{"issue":"2","key":"zoi231033r8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0950-3579(05)80192-X","article-title":"Assessing the activity of rheumatoid arthritis.","volume":"9","author":"Boers","year":"1995","journal-title":"Baillieres Clin Rheumatol"},{"issue":"8","key":"zoi231033r9","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/1529-0131(199808)41:8<1470::AID-ART18>3.0.CO;2-V","article-title":"Radiographic progression in rheumatoid arthritis: a long-term prospective study of 109 patients.","volume":"41","author":"Graudal","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"10","key":"zoi231033r10","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.","volume":"41","author":"van Gestel","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"6","key":"zoi231033r11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials.","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"5","key":"zoi231033r12","first-page":"S22","article-title":"Disease activity measures for rheumatoid arthritis.","volume":"25","author":"Dougados","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"zoi231033r13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi231033r14","first-page":"1624","article-title":"A review of network meta-analysis comparing biologics in the treatment of rheumatoid arthritis.","volume":"24","author":"Gigliucci","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10","key":"zoi231033r16","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/art.27592","article-title":"Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.","volume":"62","author":"Graudal","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"zoi231033r17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kep331","article-title":"A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.","volume":"49","author":"Ma","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"zoi231033r18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/art.1780370406","article-title":"Reduced joint counts in controlled clinical trials in rheumatoid arthritis.","volume":"37","author":"Fuchs","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"2","key":"zoi231033r19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cpt.2023","article-title":"Model-based meta-analysis compares DAS28 rheumatoid arthritis treatment effects and suggests an expedited trial design for early clinical development.","volume":"109","author":"Leil","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"zoi231033r21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"zoi231033r22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.14.4.353","article-title":"Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis; results up to one year.","volume":"14","author":"Empire Rheumatism Council","year":"1955","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"zoi231033r23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/ard.15.3.251","article-title":"Chloroquine and rheumatoid arthritis; a short-term controlled trial.","volume":"15","author":"Freedman","year":"1956","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"zoi231033r24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/ard.18.3.173","article-title":"A comparison of prednisolone with aspirin on other analgesics in the treatment of rheumatold rthritis.","volume":"18","year":"1959","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"zoi231033r25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/ard.19.3.243","article-title":"Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year.","volume":"19","author":"Freedman","year":"1960","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"zoi231033r26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard.19.2.95","article-title":"Gold therapy in rheumatoid arthritis: report of a multicentre control trial.","volume":"19","author":"The Research Sub-Committee of the Empire Rheumatism Council","year":"1960","journal-title":"Ann Rheum Dis"},{"key":"zoi231033r27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/art.1780050507","article-title":"Hydroxychloroquine sulfate (\u201cplaguenil\u201d) in treatment of rheumatoid arthritis.","volume":"5","author":"Hamilton","year":"1962","journal-title":"Arthritis Rheum"},{"key":"zoi231033r28","first-page":"287","article-title":"Hydroxychloroquine sulfate in rheumatoid arthritis: a six month double-blind trial.","volume":"13","author":"Mainland","year":"1962","journal-title":"Bull Rheum Dis"},{"issue":"17","key":"zoi231033r29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM197010222831701","article-title":"A controlled trial of cyclophosphamide in rheumatoid arthritis.","volume":"283","author":"Cooperating Clinics Committee of the American Rheumatism Association","year":"1970","journal-title":"N Engl J Med"},{"issue":"7798","key":"zoi231033r30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(73)91536-5","article-title":"Controlled trial of D(-)penicillamine in severe rheumatoid arthritis.","volume":"1","author":"Multicentre Trial Group","year":"1973","journal-title":"Lancet"},{"issue":"2","key":"zoi231033r31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.1780160203","article-title":"Double-blind study of cyclophosphamide in rheumatoid arthritis.","volume":"16","author":"Lidsky","year":"1973","journal-title":"Arthritis Rheum"},{"issue":"3","key":"zoi231033r32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.1780160309","article-title":"A controlled trial of gold salt therapy in rheumatoid arthritis.","volume":"16","author":"Cooperating Clinics Committee of the American Rheumatism Association","year":"1973","journal-title":"Arthritis Rheum"},{"issue":"1","key":"zoi231033r33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-80-1-21","article-title":"Gold salts in the treatment of rheumatoid arthritis: a double-blind study.","volume":"80","author":"Sigler","year":"1974","journal-title":"Ann Intern Med"},{"issue":"6","key":"zoi231033r34","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/ard.33.6.532","article-title":"Trial comparing D-penicillamine and gold in rheumatoid arthritis: preliminary report.","volume":"33","author":"Huskisson","year":"1974","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"zoi231033r35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/ard.34.5.416","article-title":"Synthetic D(-)penicillamine in rheumatoid arthritis: double-blind controlled study of a high and low dosage regimen.","volume":"34","author":"Dixon","year":"1975","journal-title":"Ann Rheum Dis"},{"issue":"6017","key":"zoi231033r36","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bmj.1.6017.1052","article-title":"Azathioprine and penicillamine in treatment of rheumatoid arthritis: a controlled trial.","volume":"1","author":"Berry","year":"1976","journal-title":"Br Med J"},{"issue":"3","key":"zoi231033r37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/art.1780190308","article-title":"Controlled trial of cyclophosphamide in rheumatoid arthritis.","volume":"19","author":"Townes","year":"1976","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi231033r38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/03009747609099913","article-title":"Controlled trial of D-penicillamine in rheumatoid arthritis: dose effect and the role of zinc.","volume":"5","author":"Mery","year":"1976","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"zoi231033r39","first-page":"62","article-title":"Comparison of gold and orgotein treatment in rheumatoid arthritis.","volume":"20","author":"Walravens","year":"1976","journal-title":"Curr Ther Res Clin Exp"},{"issue":"8","key":"zoi231033r40","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/art.1780200801","article-title":"Treatment of rheumatoid arthritis with levamisole: a controlled trial.","volume":"20","author":"Runge","year":"1977","journal-title":"Arthritis Rheum"},{"issue":"2","key":"zoi231033r41","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/art.1780200208","article-title":"Azathioprine in early rheumatoid arthritis: comparison with gold and chloroquine.","volume":"20","author":"Dwosh","year":"1977","journal-title":"Arthritis Rheum"},{"issue":"187","key":"zoi231033r42","first-page":"385","article-title":"Clinical and laboratory studies of levamisole in patients with rheumatoid arthritis.","volume":"47","author":"El-Ghobarey","year":"1978","journal-title":"Q J Med"},{"issue":"1","key":"zoi231033r43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/ard.37.1.93","article-title":"Alclofenac and D-penicillamine: comparative trial in rheumatoid arthritis.","volume":"37","author":"Berry","year":"1978","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"zoi231033r44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/03009747809095648","article-title":"Comparison of penicillamine and gold treatment in early rheumatoid arthritis.","volume":"7","author":"M\u00e4kisara","year":"1978","journal-title":"Scand J Rheumatol"},{"issue":"8098","key":"zoi231033r45","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(78)92335-8","article-title":"Levamisole in rheumatoid arthritis: a randomised double-blind study comparing two dosage regimens of levamisole with placebo: multicentre study group.","volume":"2","author":"Multicentre study group","year":"1978","journal-title":"Lancet"},{"issue":"4","key":"zoi231033r46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/03009747809095657","article-title":"Serum sulfhydryl levels in rheumatoid patients treated with gold thiomalate and penicillamine.","volume":"7","author":"Haataja","year":"1978","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"zoi231033r47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/art.1780230207","article-title":"Double-blind placebo controlled crossover evaluation of levamisole in rheumatoid arthritis.","volume":"23","author":"Miller","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi231033r48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/ard.40.4.355","article-title":"Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo.","volume":"40","author":"Woodland","year":"1981","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"zoi231033r49","first-page":"730","article-title":"Levamisole\u2014a possible alternative to gold and penicillamine in the longterm treatment of rheumatoid arthritis?","volume":"8","author":"Capell","year":"1981","journal-title":"J Rheumatol"},{"issue":"4","key":"zoi231033r50","first-page":"575","article-title":"Levamisole in rheumatoid arthritis: a comparison with D-penicillamine.","volume":"8","author":"Mowat","year":"1981","journal-title":"J Rheumatol"},{"key":"zoi231033r51","first-page":"190","article-title":"An open comparative study of auranofin vs. gold sodium thiomalate.","volume":"8","author":"Smith","year":"1982","journal-title":"J Rheumatol Suppl"},{"key":"zoi231033r52","first-page":"197","article-title":"A comparative study of auranofin, gold sodium thiomalate, and D-penicillamine in rheumatoid arthritis: a progress report.","volume":"8","author":"Barraclough","year":"1982","journal-title":"J Rheumatol Suppl"},{"issue":"2","key":"zoi231033r54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/ard.41.2.159","article-title":"Levamisole in rheumatoid arthritis: final report on a randomised double-blind study comparing a single weekly dose of levamisole with placebo.","volume":"41","author":"Multicentre Study Group","year":"1982","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"zoi231033r55","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/art.1780250803","article-title":"Controlled multicenter trial of tiopronin and d-penicillamine for rheumatoid arthritis.","volume":"25","author":"Pasero","year":"1982","journal-title":"Arthritis Rheum"},{"issue":"6A","key":"zoi231033r56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0002-9343(83)90487-4","article-title":"A 12-month comparative trial of auranofin and D-penicillamine in rheumatoid arthritis.","volume":"75","author":"Felix-Davies","year":"1983","journal-title":"Am J Med"},{"issue":"4","key":"zoi231033r57","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF02041557","article-title":"A comparative trial of timegadine and D-penicillamine in rheumatoid arthritis.","volume":"2","author":"Mbuyi-Muamba","year":"1983","journal-title":"Clin Rheumatol"},{"issue":"6","key":"zoi231033r58","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1445-5994.1983.tb02607.x","article-title":"A comparison of low dose levamisole and penicillamine in rheumatoid arthritis.","volume":"13","author":"Clemens","year":"1983","journal-title":"Aust N Z J Med"},{"issue":"1","key":"zoi231033r59","first-page":"4","article-title":"A double-blind one year clinical trial comparing alclofenac with gold in rheumatoid arthritis.","volume":"15","author":"Kadir","year":"1983","journal-title":"Ann Clin Res"},{"issue":"6A","key":"zoi231033r60","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0002-9343(83)90484-9","article-title":"Auranofin versus placebo in the treatment of rheumatoid arthritis.","volume":"75","author":"Wenger","year":"1983","journal-title":"Am J Med"},{"issue":"3","key":"zoi231033r61","first-page":"279","article-title":"Long-term treatment of rheumatoid arthritis with fenclofenac or gold: a controlled, single blind trial comparing clinical and biochemical parameters.","volume":"6","author":"Lund","year":"1983","journal-title":"Eur J Rheumatol Inflamm"},{"issue":"5","key":"zoi231033r62","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780260502","article-title":"Low-dose D-penicillamine therapy in rheumatoid arthritis: a controlled, double-blind clinical trial.","volume":"26","author":"Williams","year":"1983","journal-title":"Arthritis Rheum"},{"issue":"6A","key":"zoi231033r63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0002-9343(83)90486-2","article-title":"Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: subsets of responses.","volume":"75","author":"Ward","year":"1983","journal-title":"Am J Med"},{"issue":"6399","key":"zoi231033r64","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/bmj.287.6399.1099","article-title":"Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.","volume":"287","author":"Neumann","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"5","key":"zoi231033r65","first-page":"615","article-title":"A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis.","volume":"11","author":"Shiokawa","year":"1984","journal-title":"J Rheumatol"},{"issue":"2","key":"zoi231033r66","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/ard.43.2.200","article-title":"Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study.","volume":"43","author":"Fowler","year":"1984","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"zoi231033r67","first-page":"403","article-title":"Double-blind trial of levamisole, penicillamine and azathioprine in rheumatoid arthritis: clinical, biochemical, radiological and scintigraphic studies.","volume":"31","author":"Halberg","year":"1984","journal-title":"Dan Med Bull"},{"issue":"7","key":"zoi231033r68","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780270701","article-title":"Azathioprine versus D-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold.","volume":"27","author":"Paulus","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"1","key":"zoi231033r69","first-page":"60","article-title":"One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis.","volume":"12","author":"Davis","year":"1985","journal-title":"J Rheumatol"},{"issue":"7","key":"zoi231033r70","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780280702","article-title":"Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial.","volume":"28","author":"Williams","year":"1985","journal-title":"Arthritis Rheum"},{"issue":"13","key":"zoi231033r71","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis.","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi231033r72","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/0003-4819-103-4-489","article-title":"Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double-blind study.","volume":"103","author":"Andersen","year":"1985","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi231033r73","doi-asserted-by":"crossref","first-page":"528","DOI":"10.7326\/0003-4819-105-4-528","article-title":"Auranofin or D-penicillamine in the treatment of rheumatoid arthritis.","volume":"105","author":"Hochberg","year":"1986","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi231033r74","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0002-9343(86)90539-5","article-title":"Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trial.","volume":"81","author":"Bombardier","year":"1986","journal-title":"Am J Med"},{"issue":"1","key":"zoi231033r75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/03009748609092663","article-title":"Auranofin versus penicillamine in rheumatoid arthritis: one-year results from a prospective clinical investigation.","volume":"15","author":"Manthorpe","year":"1986","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"zoi231033r76","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/ard.45.9.726","article-title":"Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.","volume":"45","author":"van Rijthoven","year":"1986","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"zoi231033r77","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/art.1780291202","article-title":"Sulfasalazine in rheumatoid arthritis: a double-blind, placebo-controlled trial.","volume":"29","author":"Pinals","year":"1986","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi231033r78","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780300401","article-title":"Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty-four-week controlled clinical trial.","volume":"30","author":"Hamdy","year":"1987","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi231033r79","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/rheumatology\/26.4.279","article-title":"Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis\u2014a comparative study.","volume":"26","author":"Gibson","year":"1987","journal-title":"Br J Rheumatol"},{"issue":"6","key":"zoi231033r80","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.1780310602","article-title":"A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis.","volume":"31","author":"Williams","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"7","key":"zoi231033r81","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/ard.47.7.582","article-title":"A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis.","volume":"47","author":"Vischer","year":"1988","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"zoi231033r82","first-page":"753","article-title":"A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis.","volume":"15","author":"Suarez-Almazor","year":"1988","journal-title":"J Rheumatol"},{"issue":"4","key":"zoi231033r83","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF01727786","article-title":"Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year, double-blind, comparative multicenter study.","volume":"66","author":"Schattenkirchner","year":"1988","journal-title":"Klin Wochenschr"},{"issue":"11","key":"zoi231033r84","doi-asserted-by":"crossref","first-page":"863","DOI":"10.7326\/0003-4819-109-11-863","article-title":"Cyclosporin A in severe, treatment-refractory rheumatoid arthritis: a randomized study.","volume":"109","author":"Yocum","year":"1988","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi231033r85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.47.2.127","article-title":"Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients.","volume":"47","author":"Dougados","year":"1988","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"zoi231033r86","first-page":"1747","article-title":"Auranofin improves outcome in early rheumatoid arthritis: results from a 2-year, double blind placebo controlled study.","volume":"15","author":"Borg","year":"1988","journal-title":"J Rheumatol"},{"issue":"5","key":"zoi231033r87","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/ard.48.5.389","article-title":"A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.","volume":"48","author":"Nuver-Zwart","year":"1989","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"zoi231033r88","first-page":"302","article-title":"Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis\u2014a randomized, double blind 26-week trial.","volume":"16","author":"Morassut","year":"1989","journal-title":"J Rheumatol"},{"issue":"6","key":"zoi231033r89","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00270980","article-title":"Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis.","volume":"8","author":"Carroll","year":"1989","journal-title":"Rheumatol Int"},{"issue":"2","key":"zoi231033r90","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/rheumatology\/29.2.120","article-title":"Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study.","volume":"29","author":"Arnold","year":"1990","journal-title":"Br J Rheumatol"},{"issue":"276","key":"zoi231033r91","first-page":"335","article-title":"Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period.","volume":"75","author":"Capell","year":"1990","journal-title":"Q J Med"},{"issue":"8697","key":"zoi231033r92","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(90)92630-Z","article-title":"Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.","volume":"335","author":"Tugwell","year":"1990","journal-title":"Lancet"},{"issue":"3","key":"zoi231033r93","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/art.1780330305","article-title":"Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis: a thirty-six-week, double-blind trial.","volume":"33","author":"Weinblatt","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"6","key":"zoi231033r94","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/03009749009097631","article-title":"OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis: a 12-month double-blind randomized study.","volume":"19","author":"Verstraeten","year":"1990","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"zoi231033r95","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/rheumatology\/29.2.126","article-title":"Radiological progression in rheumatoid arthritis: do D-penicillamine and hydroxychloroquine have different effects?","volume":"29","author":"Scott","year":"1990","journal-title":"Br J Rheumatol"},{"issue":"6","key":"zoi231033r96","first-page":"815","article-title":"Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study.","volume":"18","author":"van Rijthoven","year":"1991","journal-title":"J Rheumatol"},{"issue":"6","key":"zoi231033r97","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1445-5994.1991.tb01405.x","article-title":"A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis.","volume":"21","author":"Ahern","year":"1991","journal-title":"Aust N Z J Med"},{"issue":"8","key":"zoi231033r98","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/art.1780340805","article-title":"Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight-week randomized, double-blind trial.","volume":"34","author":"Jeurissen","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"1","key":"zoi231033r99","first-page":"90","article-title":"Sulphasalazine in early rheumatoid arthritis.","volume":"9","author":"Reilly","year":"1991","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"zoi231033r100","first-page":"328","article-title":"A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis.","volume":"18","author":"Rau","year":"1991","journal-title":"J Rheumatol"},{"issue":"3","key":"zoi231033r101","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/art.1780350304","article-title":"Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial.","volume":"35","author":"Williams","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"8","key":"zoi231033r102","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/art.1780350802","article-title":"Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial.","volume":"35","author":"Willkens","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"5","key":"zoi231033r103","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/ard.51.5.600","article-title":"Controlled trial of methotrexate versus 10-deazaaminopterin in the treatment of rheumatoid arthritis.","volume":"51","author":"Alarc\u00f3n","year":"1992","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"zoi231033r104","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/ard.51.4.461","article-title":"Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis.","volume":"51","author":"Porter","year":"1992","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"zoi231033r105","first-page":"1672","article-title":"Sulfasalazine in early rheumatoid arthritis.","volume":"19","author":"The Australian Multicentre Clinical Trial Group","year":"1992","journal-title":"J Rheumatol"},{"issue":"5","key":"zoi231033r106","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/rheumatology\/32.5.375","article-title":"Comparison of pyritinol and auranofin in the treatment of rheumatoid arthritis.","volume":"32","author":"Lemmel","year":"1993","journal-title":"Br J Rheumatol"},{"issue":"10","key":"zoi231033r107","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/ard.52.10.711","article-title":"Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial.","volume":"52","author":"Faarvang","year":"1993","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"zoi231033r108","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.7326\/0003-4819-119-11-199312010-00002","article-title":"Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial.","volume":"119","author":"Clark","year":"1993","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi231033r109","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/art.1780361104","article-title":"Sulfasalazine in early rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study.","volume":"36","author":"Hannonen","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"3","key":"zoi231033r110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/03009749309099254","article-title":"A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis.","volume":"22","author":"Haar","year":"1993","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"zoi231033r111","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/art.1780370506","article-title":"A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis.","volume":"37","author":"Landew\u00e9","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"2","key":"zoi231033r112","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF02249021","article-title":"Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis\u2014results of a double-blind multicentre study.","volume":"13","author":"Kr\u00fcger","year":"1994","journal-title":"Clin Rheumatol"},{"issue":"1","key":"zoi231033r113","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/BF02229866","article-title":"Prospidine versus methotrexate pulse in highly active rheumatoid arthritis: a controlled 6-month clinical trial.","volume":"13","author":"Benenson","year":"1994","journal-title":"Clin Rheumatol"},{"issue":"9","key":"zoi231033r114","first-page":"591","article-title":"Comparaison de l'azathioprine et du m\u00e9thotrexate dans la polyarthrite rhumato\u00efde: une \u00e9tude clinique ouverte randomis\u00e9e. Comparison of azathioprine and methotrexate in rheumatoid arthritis: an open-randomized clinical study.","volume":"61","author":"Westedt","year":"1994","journal-title":"Rev Rhum Ed Fr"},{"issue":"10","key":"zoi231033r115","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/art.1780381011","article-title":"Tenidap in rheumatoid arthritis: a 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone.","volume":"38","author":"Blackburn","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"7","key":"zoi231033r116","first-page":"1235","article-title":"Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis\u2014a double blind study.","volume":"22","author":"Rao","year":"1995","journal-title":"J Rheumatol"},{"issue":"5","key":"zoi231033r117","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/BF02208150","article-title":"A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis.","volume":"14","author":"Farr","year":"1995","journal-title":"Clin Rheumatol"},{"issue":"2","key":"zoi231033r118","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0002-9343(99)80399-4","article-title":"A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study.","volume":"98","author":"The HERA Study Group","year":"1995","journal-title":"Am J Med"},{"issue":"3","key":"zoi231033r119","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.1780380307","article-title":"Prednisone treatment of elderly-onset rheumatoid arthritis: disease activity and bone mass in comparison with chloroquine treatment.","volume":"38","author":"van Schaardenburg","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"11","key":"zoi231033r120","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.1780381111","article-title":"Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study.","volume":"38","author":"Mladenovic","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi231033r121","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/BF02207682","article-title":"Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.","volume":"14","author":"Salaffi","year":"1995","journal-title":"Clin Rheumatol"},{"issue":"1","key":"zoi231033r122","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/PL00006849","article-title":"A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis.","volume":"17","author":"Kim","year":"1997","journal-title":"Rheumatol Int"},{"issue":"10","key":"zoi231033r123","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/rheumatology\/36.10.1082","article-title":"Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial.","volume":"36","author":"Haagsma","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"3","key":"zoi231033r124","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/rheumatology\/36.3.345","article-title":"Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients.","volume":"36","author":"Rau","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"8","key":"zoi231033r125","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/37.8.874","article-title":"Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold.","volume":"37","author":"Zeidler","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"1","key":"zoi231033r126","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/030097498441137","article-title":"CPH-82 (Reumacon) versus auranofin (Ridaura): a 36-week study of their respective onset of action rates in RA.","volume":"27","author":"Bj\u00f8rneboe","year":"1998","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"zoi231033r127","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/ard.58.4.220","article-title":"Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.","volume":"58","author":"Dougados","year":"1999","journal-title":"Ann Rheum Dis"},{"issue":"9149","key":"zoi231033r128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial.","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"issue":"21","key":"zoi231033r129","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate.","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"issue":"10","key":"zoi231033r130","first-page":"2102","article-title":"Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study.","volume":"26","author":"Altman","year":"1999","journal-title":"J Rheumatol"},{"issue":"3","key":"zoi231033r131","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/rheumatology\/39.3.316","article-title":"A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis.","volume":"39","author":"Lerndal","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"zoi231033r132","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"zoi231033r133","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/1529-0131(200007)43:7<1488::AID-ANR11>3.0.CO;2-G","article-title":"Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.","volume":"43","author":"Kraan","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"8","key":"zoi231033r134","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D","article-title":"Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.","volume":"43","author":"Kraan","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"1","key":"zoi231033r135","first-page":"19","article-title":"The open randomised trial of cyclosporine vs methotrexate in refractory rheumatoid arthritis.","volume":"3","author":"Singh","year":"2000","journal-title":"Journal of Internal Medicine of India"},{"issue":"6","key":"zoi231033r136","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/ard.60.6.566","article-title":"Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area.","volume":"60","author":"Hamilton","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"zoi231033r137","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/art.10427","article-title":"Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.","volume":"46","author":"Furst","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"1","key":"zoi231033r138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","article-title":"Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.","volume":"136","author":"van Everdingen","year":"2002","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi231033r139","first-page":"351","article-title":"Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium.","volume":"20","author":"Choy","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"zoi231033r140","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1002\/art.11363","article-title":"Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial.","volume":"48","author":"Yocum","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"8","key":"zoi231033r141","first-page":"1228","article-title":"Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.","volume":"116","author":"Bao","year":"2003","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"zoi231033r142","first-page":"243","article-title":"Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.","volume":"31","author":"Kondo","year":"2004","journal-title":"J Rheumatol"},{"issue":"1","key":"zoi231033r143","first-page":"1","article-title":"Clinical efficacy and safety evaluation of eazmov plus in rheumatoid arthritis.","volume":"7","author":"Rani","year":"2006","journal-title":"Phytomedica"},{"issue":"7","key":"zoi231033r144","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00029330-200804010-00008","article-title":"Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.","volume":"121","author":"L\u00fc","year":"2008","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"zoi231033r145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi231033r146","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-151-4-200908180-00005","article-title":"Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.","volume":"151","author":"Goldbach-Mansky","year":"2009","journal-title":"Ann Intern Med"},{"issue":"7","key":"zoi231033r147","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/art.24643","article-title":"Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"zoi231033r148","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11537460-000000000-00000","article-title":"Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials.","volume":"30","author":"Schiff","year":"2010","journal-title":"Clin Drug Investig"},{"issue":"4","key":"zoi231033r149","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/s10165-010-0405-4","article-title":"Leflunomide or methotrexate: comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients.","volume":"21","author":"Ishaq","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"6","key":"zoi231033r150","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2013-204807","article-title":"Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial.","volume":"74","author":"Lv","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"zoi231033r151","first-page":"2353","article-title":"Analysis of efficacy and safety of treatment of active rheumatoid arthritis with iguratimod and methotrexate.","volume":"28","author":"Zhao","year":"2017","journal-title":"Biomed Res (Aligarh)"},{"key":"zoi231033r152","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2288-1-6","article-title":"The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study.","volume":"1","author":"Vickers","year":"2001","journal-title":"BMC Med Res Methodol"},{"issue":"20","key":"zoi231033r153","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons.","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"issue":"5","key":"zoi231033r154","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials.","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"zoi231033r155","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS\u2014a bayesian modelling framework: concepts, structure, and extensibility.","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"issue":"4","key":"zoi231033r156","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations.","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"issue":"5","key":"zoi231033r158","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity\u2013subgroups, meta-regression, bias, and bias-adjustment.","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"zoi231033r159","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-198600321-00006","article-title":"5-Aminosalicylic acid or sulphapyridine: which is the active moiety of sulphasalazine in rheumatoid arthritis?","volume":"32","author":"Taggart","year":"1986","journal-title":"Drugs"},{"issue":"6","key":"zoi231033r160","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"zoi231033r161","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","article-title":"Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis.","volume":"54","author":"Faurschou","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"zoi231033r162","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.17053","article-title":"Association of patient, prescriber, and region with the initiation of first prescription of biologic disease-modifying antirheumatic drug among older patients with rheumatoid arthritis and identical health insurance coverage.","volume":"2","author":"Tatangelo","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi231033r163","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106408","article-title":"Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials.","volume":"9","author":"Graudal","year":"2014","journal-title":"PLoS One"},{"key":"zoi231033r164","doi-asserted-by":"crossref","first-page":"h1046","DOI":"10.1136\/bmj.h1046","article-title":"Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.","volume":"350","author":"Scott","year":"2015","journal-title":"BMJ"},{"issue":"11","key":"zoi231033r165","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/acr.22618","article-title":"Combination therapy with and without tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis of randomized trials.","volume":"67","author":"Graudal","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"zoi231033r166","article-title":"Sulfasalazine for rheumatoid arthritis.","volume":"1998","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi231033r167","article-title":"Injectable gold for rheumatoid arthritis.","volume":"1997","author":"Clark","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi231033r168","article-title":"Auranofin versus placebo in rheumatoid arthritis.","volume":"2000","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi231033r169","article-title":"Cyclophosphamide for rheumatoid arthritis.","volume":"2","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi231033r170","article-title":"Azathioprine for rheumatoid arthritis.","volume":"2","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi231033r171","article-title":"Penicillamine for rheumatoid arthritis.","volume":"2","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"zoi231033r172","article-title":"Leflunomide for treating rheumatoid arthritis.","volume":"2002","author":"Osiri","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"1-2","key":"zoi231033r173","doi-asserted-by":"crossref","first-page":"22","DOI":"10.20452\/pamw.1131","article-title":"Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.","volume":"122","author":"Golicki","year":"2012","journal-title":"Pol Arch Med Wewn"},{"issue":"8","key":"zoi231033r174","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis.","volume":"2016","author":"Hazlewood","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"zoi231033r175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.reuma.2017.07.020","article-title":"Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.","volume":"15","author":"Alfaro-Lara","year":"2019","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"8","key":"zoi231033r176","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement.","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"10","key":"zoi231033r178","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/art.38784","article-title":"Randomized controlled trials of rheumatoid arthritis registered at ClinicalTrials.gov: what gets published and when.","volume":"66","author":"Khan","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"zoi231033r179","first-page":"2112","article-title":"Should tetracycline treatment be used more extensively for rheumatoid arthritis: metaanalysis demonstrates clinical benefit with reduction in disease activity.","volume":"30","author":"Stone","year":"2003","journal-title":"J Rheumatol"},{"key":"zoi231033r53","first-page":"147","volume-title":"Auranofin, Proceedings of a Smith Kline & French International Symposium","author":"Lewis","year":"1983"},{"key":"zoi231033r15","unstructured":"DANBIO. National Annual Report of the Danish Rheumatology Register 2019. Landsd\u00e6kkende klinisk kvalitetsdatabase for behandling af reumatologiske patienter National \u00c5rsrapport 2019. Accessed August 29, 2023. https:\/\/www.sundhed.dk\/content\/cms\/91\/4691_danbio-aarsrapport-2019_endeligversion.pdf"},{"key":"zoi231033r20","unstructured":"R Core Team. The R Project for Statistical Computing. Accessed August 29, 2923. https:\/\/www.r-project.org\/"},{"key":"zoi231033r157","unstructured":"Daly? C, Downing? BC, Welton? NJ. A practical guide to inconsistency checks in bayesian network meta-analysis. Accessed August 29, 2023. https:\/\/www.bristol.ac.uk\/media-library\/sites\/social-community-medicine\/documents\/mpes\/Guide%20to%20Checking%20for%20Inconsistency%20in%20NMA_TSU.pdf"},{"key":"zoi231033r177","unstructured":"National Library of Medicine. About ClinicalTrials.gov. Accessed August 29, 2023. https:\/\/clinicaltrials.gov\/ct2\/about-site\/background"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2810260\/guski_2023_oi_231033_1695845428.4388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T07:10:47Z","timestamp":1730272247000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2810260"}},"subtitle":["A Network Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":179,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.35950","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]}}}